Owlstone Inc. is a diagnostics-focused company that works in the field of breath-based testing and breath biopsy diagnostics.
Subscribe to see Owlstone Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Owlstone Inc. is a biotechnology company headquartered in Westport, United States. It has raised at least $10.1M across the 4 funding rounds on record. Its most recent funding round raised $908,000 in July 2023. Xcout tracks 16 named people at Owlstone Inc., including Bret Bader (CEO Owlstone Inc).
As of 16 November 2026. Source: Xcout Intel.
10 more named people on record for Owlstone Inc., with roles, board committees and tenure — see the full roster →
At least $10.1M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $908,000 | — | |
| SEC Form D filing | $1.5M | — | |
| SEC Form D filing | $679,000 | — | |
| Seed | $7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Owlstone Inc.'s closest competitors — see the full list of competitors and alternatives →
Rua Diagnostics Inc. is a medical technology company developing breath-based diagnostic testing technology using gas chromatography and AI/ML software analysis. The company focuses on investigational diagnostic solutions for detecting conditions such as lung cancer, colorectal cancer, and COVID-19 variants.
Exosome Diagnostics, Inc. is a molecular diagnostics company located in Massachusetts, United States. The company specializes in developing biofluid-based liquid biopsy tests, such as the ExoDx Prostate test, for use in personalized medicine and oncology.
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
ExosomeDx (Exosome Diagnostics) develops noninvasive liquid-biopsy diagnostics based on RNA carried in exosomes, including the ExoDx Prostate test for assessing prostate-cancer risk. Its products serve urologists, oncologists, laboratories, and patients by supporting clinical decision-making without relying solely on invasive biopsy.
Liquid BioScience, Inc. is a biotechnology company operating within the United States, focusing on advanced analytics and diagnostics in the biotech sector.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Owlstone Inc.? Suggest a correction · Work at Owlstone Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.